Virtual Library
Start Your Search
Charles Butts
Author of
-
+
MS18 - Management of SCLC Patients Not Represented in Clinical Trials (ID 797)
- Event: WCLC 2018
- Type: Mini Symposium
- Track: Small Cell Lung Cancer/NET
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 13:30 - 15:00, Room 206 BD
-
+
MS18.04 - Retreatment with Platinum and Etoposide and Treatment Beyond Second Line (ID 11480)
14:30 - 14:50 | Presenting Author(s): Charles Butts
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
P2.17 - Treatment of Locoregional Disease - NSCLC (Not CME Accredited Session) (ID 966)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.17-28 - Real-World Data: Survival Outcomes of Chemotherapy Regimens Given Concurrently with Radiotherapy for Locally Advanced NSCLC (ID 12013)
16:45 - 18:00 | Author(s): Charles Butts
- Abstract
Background
Initial management for inoperable Stage III non-small cell lung cancer (NSCLC) treated for curative intent is platinum-based chemotherapy with concurrent thoracic radiotherapy (TRT). However, a lack of consensus on the optimal chemotherapy regimen administered with TRT remains. In Alberta, Canada, cisplatin/etoposide (EP), given Days 1-5 + 8 of a 28-day cycle, and cisplatin/vinorelbine (VP), given Days 1 +8 of a 21-day cycle, have been the two regimens used preferentially. Weekly carboplatin/paclitaxel (CP) has historically been used as an alternative in patients (pts) with borderline performance status or contraindication to cisplatin. Here, we retrospectively compare survival outcomes of these chemotherapy regimens.
a9ded1e5ce5d75814730bb4caaf49419 Method
The Alberta Cancer Registry identified pts diagnosed with locally advanced NSCLC between 2010 and 2015 and treated with EP, VP or CP chemotherapy with concurrent TRT. Patient and tumour characteristics were collected along with treatment parameters. Progression-free survival (PFS) and overal survival (OS) was determined for each chemotherapy regimen. Survival outcomes were compared using Kaplan-Meier analysis and Cox proportional hazard regression models adjusting for age, gender, tumour histological subtype (squamous vs. non-squamous NSCLC) and 7th edition TNM Stage (IIIA vs. IIIB).
4c3880bb027f159e801041b1021e88e8 Result
Of 148 pts reviewed, 44, 79, and 25 pts were treated with EP, VP, and CP, respectively, with median ages of 63, 62, and 68 years. Gender, tumour histological subtype, distribution of Stage IIIA vs. IIIB, and use of PET imaging for staging were balanced between regimens. Median PFS (EP 9.5 mo; VP 12.9 mo; CP 11.2 mo; p=0.875) and OS (EP 17.8 mo; VP 25.3 mo; CP 33.2 mo; p=0.509) were not significantly affected. Non-squamous median OS (EP 33.4 mo; VP 31.0 mo; CP 33.2 mo; p=0.997) and squamous median OS (EP 13.4 mo; VP 22.3 mo; CP not reached (N=11); p=0.406) also did not differ by regimen. Multivariate Cox regression analysis demonstrated Stage (IIIA vs. IIIB) as the only parameter that significantly altered PFS and OS.
8eea62084ca7e541d918e823422bd82e Conclusion
This retrospective analysis of real-word data from 2010 to 2015, in the absence of consolidation durvalumab, shows that PFS and OS in locally advanced NSCLC pts treated with concurrent chemoradiotherapy are similar for the EP, VP or CP regimens. Dose scheduling and respective toxicities will likely determine choice of chemotherapy regimen given with TRT. Further review of the CP regimen, given the small sample size in this study, and the use of next generation chemotherapy regimens such as platinum/pemetrexed for non-squamous NSCLC is warranted.
6f8b794f3246b0c1e1780bb4d4d5dc53
